RU2008138534A - Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам - Google Patents
Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам Download PDFInfo
- Publication number
- RU2008138534A RU2008138534A RU2008138534/15A RU2008138534A RU2008138534A RU 2008138534 A RU2008138534 A RU 2008138534A RU 2008138534/15 A RU2008138534/15 A RU 2008138534/15A RU 2008138534 A RU2008138534 A RU 2008138534A RU 2008138534 A RU2008138534 A RU 2008138534A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical combination
- combination according
- cytostatic substance
- cytostatic
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
1. Фармацевтическая комбинация для одновременного, раздельного или последовательного введения, которая содержит ингибитор сайта фосфорилирования на субстратах СК2 наряду с цитостатическим веществом, фармацевтически приемлемо смешанным с соответствующими переносчиками. ! 2. Фармацевтическая комбинация по п.1, в которой ингибитор сайта фосфорилирования на субстратах СК2 включает пептид Р15 (CWMSPRHLGTC). ! 3. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является химическим соединением, которое принадлежит к платинам (карбоплатин и цисплатин), таксолам (пакситаксел и досетаксел) и алкалоидам Vinca (винкристин и винблатин). ! 4. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является 5-фторурацилом. ! 5. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является доксорубицином. ! 6. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является циклофосфамидом. ! 7. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Митомицином С. ! 8. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Велкадом (вортезомибом). ! 9. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Ирессой. ! 10. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Иматинибом. ! 11. Применение фармацевтических комбинаций по пп.1-10 для обхода химической устойчивости солидных и гематопоэтических опухолей к фармацевтически приемлемым цитостатическим веществом и, где ингредиенты фармацевтической комбинации вводятся одновременно, разд
Claims (15)
1. Фармацевтическая комбинация для одновременного, раздельного или последовательного введения, которая содержит ингибитор сайта фосфорилирования на субстратах СК2 наряду с цитостатическим веществом, фармацевтически приемлемо смешанным с соответствующими переносчиками.
2. Фармацевтическая комбинация по п.1, в которой ингибитор сайта фосфорилирования на субстратах СК2 включает пептид Р15 (CWMSPRHLGTC).
3. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является химическим соединением, которое принадлежит к платинам (карбоплатин и цисплатин), таксолам (пакситаксел и досетаксел) и алкалоидам Vinca (винкристин и винблатин).
4. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является 5-фторурацилом.
5. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является доксорубицином.
6. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является циклофосфамидом.
7. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Митомицином С.
8. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Велкадом (вортезомибом).
9. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Ирессой.
10. Фармацевтическая комбинация по пп.1 и 2, в которой цитостатическое вещество является Иматинибом.
11. Применение фармацевтических комбинаций по пп.1-10 для обхода химической устойчивости солидных и гематопоэтических опухолей к фармацевтически приемлемым цитостатическим веществом и, где ингредиенты фармацевтической комбинации вводятся одновременно, раздельно или последовательно.
12. Применение фармацевтических комбинаций по пп.1-10, где ингибитор сайта фосфорилирования на субстратах СК2 является химическим соединением или пептидом.
13. Применение фармацевтических комбинаций по пп.1-10, где ингибитор сайта фосфорилирования на субстратах СК2 экспрессируется в ДНК векторе.
14. Применение ингибитора сайта фосфорилирования на субстратах СК2 наряду с фармацевтически приемлемым цитостатическим веществом для получения лекарственного средства для лечения рака.
15. Применение ингибитора сайта фосфорилирования на субстратах СК2 наряду с фармацевтически приемлемым цитостатическим веществом для получения лекарственного средства для лечения химически устойчивых опухолей к цитостатическим веществам.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20060049A CU23511B6 (es) | 2006-02-28 | 2006-02-28 | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
CU2006-0049 | 2006-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008138534A true RU2008138534A (ru) | 2010-04-10 |
RU2396974C2 RU2396974C2 (ru) | 2010-08-20 |
Family
ID=40134932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008138534/15A RU2396974C2 (ru) | 2006-02-28 | 2007-02-28 | Фармацевтическая комбинация для лечения и/или хемосенсибилизации опухолей, устойчивых к противораковым средствам |
Country Status (23)
Country | Link |
---|---|
US (3) | US8871725B2 (ru) |
EP (1) | EP1997506B8 (ru) |
JP (2) | JP5733880B2 (ru) |
KR (1) | KR101454866B1 (ru) |
CN (1) | CN101432012B (ru) |
AR (1) | AR059645A1 (ru) |
AU (1) | AU2007219572B2 (ru) |
BR (1) | BRPI0708307B1 (ru) |
CA (1) | CA2642943C (ru) |
CL (1) | CL2015001086A1 (ru) |
CU (1) | CU23511B6 (ru) |
CY (1) | CY1114686T1 (ru) |
DO (1) | DOP2007000040A (ru) |
HK (1) | HK1132451A1 (ru) |
MX (1) | MX2008011141A (ru) |
MY (1) | MY150135A (ru) |
NO (1) | NO341904B1 (ru) |
PE (1) | PE20081191A1 (ru) |
PL (1) | PL1997506T3 (ru) |
RU (1) | RU2396974C2 (ru) |
UY (1) | UY30175A1 (ru) |
WO (1) | WO2007098719A1 (ru) |
ZA (1) | ZA200807323B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
CN109875998B (zh) * | 2019-01-24 | 2021-09-03 | 武汉大学 | 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物 |
CN110448699B (zh) * | 2019-06-12 | 2022-03-11 | 天津医科大学 | 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法 |
CU20200103A7 (es) * | 2020-12-18 | 2022-07-08 | Ct Ingenieria Genetica Biotecnologia | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
CN114712377B (zh) * | 2022-04-26 | 2023-08-15 | 江苏师范大学 | 断血流皂苷a在制造药物中的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
EP1487436A4 (en) * | 2002-03-08 | 2009-06-03 | Signal Pharm Inc | POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS |
US20060014987A1 (en) * | 2003-07-07 | 2006-01-19 | Lan Huang | Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof |
CA2545054A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
CA2546920A1 (en) * | 2003-12-09 | 2005-06-23 | Joel Moss | Methods for suppressing an immune response or treating a proliferative disorder |
TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2006
- 2006-02-28 CU CU20060049A patent/CU23511B6/es active IP Right Grant
-
2007
- 2007-02-23 DO DO2007000040A patent/DOP2007000040A/es unknown
- 2007-02-27 UY UY30175A patent/UY30175A1/es not_active Application Discontinuation
- 2007-02-27 AR ARP070100805A patent/AR059645A1/es not_active Application Discontinuation
- 2007-02-28 EP EP07711104A patent/EP1997506B8/en active Active
- 2007-02-28 CA CA2642943A patent/CA2642943C/en active Active
- 2007-02-28 RU RU2008138534/15A patent/RU2396974C2/ru active
- 2007-02-28 US US12/280,629 patent/US8871725B2/en active Active
- 2007-02-28 CN CN2007800152341A patent/CN101432012B/zh active Active
- 2007-02-28 WO PCT/CU2007/000010 patent/WO2007098719A1/es active Search and Examination
- 2007-02-28 PE PE2007000215A patent/PE20081191A1/es not_active Application Discontinuation
- 2007-02-28 MY MYPI20083318A patent/MY150135A/en unknown
- 2007-02-28 BR BRPI0708307-6A patent/BRPI0708307B1/pt active IP Right Grant
- 2007-02-28 KR KR1020087023587A patent/KR101454866B1/ko active IP Right Grant
- 2007-02-28 AU AU2007219572A patent/AU2007219572B2/en active Active
- 2007-02-28 MX MX2008011141A patent/MX2008011141A/es active IP Right Grant
- 2007-02-28 JP JP2008556646A patent/JP5733880B2/ja active Active
- 2007-02-28 PL PL07711104T patent/PL1997506T3/pl unknown
-
2008
- 2008-08-23 ZA ZA200807323A patent/ZA200807323B/xx unknown
- 2008-09-29 NO NO20084119A patent/NO341904B1/no not_active IP Right Cessation
-
2009
- 2009-10-29 HK HK09110055.2A patent/HK1132451A1/xx not_active IP Right Cessation
-
2013
- 2013-02-15 CY CY20131100142T patent/CY1114686T1/el unknown
- 2013-07-12 JP JP2013146681A patent/JP2013231065A/ja not_active Withdrawn
-
2014
- 2014-09-19 US US14/490,856 patent/US9226946B2/en active Active
- 2014-10-20 US US14/518,242 patent/US9278118B2/en active Active
-
2015
- 2015-04-24 CL CL2015001086A patent/CL2015001086A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008138534A (ru) | Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам | |
Ali et al. | Platinum compounds: a hope for future cancer chemotherapy | |
CN101146532B (zh) | 药物化合物 | |
RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
BRPI0517619A (pt) | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos | |
KR101230085B1 (ko) | 7―(2,5-디히드로―4-이미다조[1,2-a]피리딘-3-일-2,5-디옥소-1h-피롤-3-일)-9-플루오로-1,2,3,4-테트라히드로-2-(1-피페리디닐카르보닐)-피롤로[3,2,1-jk][1,4]벤조디아제핀에 의한 암 화학요법의 강화 | |
JP2020532556A5 (ru) | ||
TW200510392A (en) | Chemical compounds | |
ATE429435T1 (de) | 7h-pyrrolopyrimidinderivate | |
Iqbal et al. | Serendipity of cisplatin, and the emergence of metallodrugs in cancer chemotherapy | |
Eismann et al. | Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors | |
KR20140035974A (ko) | 종양 질환 치료를 위한 약제 조성물 | |
CN104146999A (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
JP2016521760A (ja) | がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ | |
Edelman | Gemcitabine and Carboplatin Regimens in Advanced Non–Small-Cell Lung Cancer: Focus on Randomized Phase III Trials | |
JP5030799B2 (ja) | アルブミン結合性薬物の安全性および効力を増大させる方法および組成物 | |
CN113797342A (zh) | 用于预防或治疗肿瘤疾病的治疗剂组合 | |
Parsons | Progress in Cancer Drug Resistance Research | |
TH94277B (th) | อนุพันธ์พิริมิดีนที่เชื่อมต่อกับออกซิเจน | |
한상훈 | The effect of bortezomib on expression of inflammatory cytokines and survival in an experimental sepsis model induced by cecal ligation and puncture | |
TH55950B (th) | อินโดลิโนนที่ถูกแทนที่ในตำแหน่ง-6, การเตรียมสารประกอบเหล่านี้ และการใช้สารเหล่านี้เป็นองค์ประกอบทางเภสัชกรรม |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20131120 |